Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/02—Antidotes
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
  • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
  • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
  • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/06—Dipeptides
  • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Definitions

• the present invention relates to novel organic compounds and compositions which antagonize cholecystokinin and gastrin, processes for making such compounds, synthetic intermediates employed in these processes and a method for treating gastrointestinal disorders, central nervous system disorders, cancers of the pancreas and the gall bladder, hypoinsulinemia, or potentiating analgesia, or regulating appetite with such compounds.
• CCK Cholecystokinins
• CCK 8 the carboxyl terminal octapeptide fragment of CCK, is the smallest CCK fragment that remains fully biologically active.
• CCK may be an important neuromodulator of memory, learning and control of primary sensory and motor functions.
• CCK and its fragments are believed to play an important role in appetite regulation and satiety.
• Della-Fera Science 206 471 (1979); Gibbs et al., Nature 289 599(1981); and Smith, Eating and Its Disorders, eds., Raven Press, New York, 67 (1984)).
• CCK antagonists B.J. Gertz in Neurology and Neurobiology Vol 47, Cholecystokinin Antagonists, Wang and Schoenfeld eds., Alan R. Liss, Inc., New York, NY, 327-342, (1988); Silverman, et al., Am. J. Gastroent. 82 703-8 (1987)) are useful in the treatment and prevention of CCK-related disorders of the gastrointestinal (GI) (Lotti, et al., J. Pharm. Exp. Therap. 241 103-9 (1987)), central nervous (CNS) (Panerai, et al., Neuropharmacology 26 1285-87 (1987)) and appetite regulatory systems of animals, especially man.
• GI gastrointestinal
• CNS central nervous
• CCK antagonists are also useful in potentiating and prolonging opiate induced analgesia and thus have utility in the treatment of pain.
• CCK antagonists are also useful for the treatment of disorders of gastric emptying (Stenikar, et al., Arzn. Forsch./Drug Research 37(II) 1168-71 (1987)), gastroesophageal reflux disease, pancreatitis, pancreatic and gastric carcinomas (Douglas, et al., Gastroent.
• the first class comprises derivatives of cyclic nucleotides as represented by dibutyryl cyclic GMP (N. Barlas et al., Am. J. Physiol., 242, G161 (1982) and references therein).
• the second class is represented by C-terminal fragments of CCK (see Jensen et al. Biochem. Bioohys. Acta, 757, 250 (1983) and Spanarkel J. Biol. Chem. 258, 6746 (1983)).
• the third class comprises amino acid derivatives of glutamic acid and tryptophan as indicated by proglumide and benzotript (see Hahne et al. Proc. Natl. Acad.
• the fourth and most recent class is comprised of 3-substituted benzodiazepines, represented by L-364,718 (see: Evans et al. Proc. Natl. Acad. Sci. U.S.A., 83 4918 (1986)).
• CCK antagonists are relatively weak antagonists of CCK demonstrating IC 50 s between 10 -4 and 10 -6 M.
• the benzodiazepine CCK antagonists or their metabolites may have undesirable effects in vivo due to their interaction with benzodiazepine receptors.
• the C-terminal pentapeptide fragment of CCK is the same as the C-terminal pentapeptide fragment of another polypeptide hormone, gastrin.
• Gastrin like CCK, exists in both the GI system. Gastrin antagonists are useful in the treatment and prevention of gastrin-related disorders of the GI system such as ulcers, Zollinger-Ellison syndrome and central G cell hyperplasia. (Morley, Gut Pept. Ulcer Proc, Hiroshima Symp. 2nd, 1, (1983)). Bock,et al., J. Med. Chem. 32 13-16 (1989) discloses receptor antagonists of the in vitro effects of gastrin.
• the compounds of the invention are antagonists of cholecystokinin (CCK) and bind specifically to CCK receptors.
• CCK antagonists are useful in the treatment and prevention of CCK-related disorders of the gastrointestinal, central nervous and appetite regulatory systems of animals and humans.
• CCK antagonists are useful in the treatment and prevention of gastrointestinal ulcers, cancers of the gall bladder and pancreas, pancreatitis, Zollinger-Ellison syndrome, central G cell hyperplasia, irritable bowel syndrome, the treatment or prevention of neurpleptic disorders, tardive dyskinesia, Parkinson's disease, psychosis, Gilles de la Tourette syndrome, disorders of appetite regulatory systems, the treatment of pain and the treatment of substance abuse.
• cholecystokinin antagonists of the formula:
• R 1 and R 2 are independently selected from i) hydrogen, ii) loweralkyl, iii) cycloalkyl, iv) loweralkenyl, v) adamantyl, vi) aryl, vii) substituted aryl, viii) heterocyclic group, ix) substituted alkyl, x) substituted amide, xi) functionalized carbonyl, and xii) nitrogen containing ring wherein R 1 ,
• R 2 and the adjacent nitrogen atom form a ring.
• R 6 and R 7 are independently selected from hydrogen, loweralkyl, cycloalkyl, loweralkenyl,
• aryl group is substituted with one, two or three substituents independently selected from loweralkyl, alkoxy, thioalkoxy, carboxy, carboalkoxy, cyano, haloalkyl, -N 3 , -NHP 4 wherein P 4 is an N-protecting group , -O P 5 wherein P 5 is an O-protecting group, nitro, halogen, hydroxy, amino, alkylamino and dialkylamino; v) -(C(R 21 )(R 18 )) 1-4 aryl wherein R 21 is hydrogen, -(C 1 -C 8 loweralkyl), loweralkenyl,
• R 1 8 is hydrogen , - ( C 1 -C 6 loweralkyl ) , loweralkenyl,
• R 4 is independently as defined above, vi) -(C(R 21 )(R 18 )) 1-4 (substituted aryl) wherein R 21 and R 18 are defined independently as above, vii) -(C(R 21 )(R 18 )) 1-4 C(O)R 3 , wherein
• R 21 and R 18 are independently as defined above and wherein R 3 is -OH, -OR 4 wherein
• R 4 is independently as defined above,
• R 6 and R 7 are independently as defined above, or -NHR 4 wherein R 4 is as defined above, with the proviso that when R 3 is NR 6 R 7 then R 21 , and R 18 are not both hydrogen and viii) -(C(R 21 )(R 18 )) 1-4 R 12 wherein
• R 21 and R 18 are independently as defined above and R 12 is a heterocyclic group.
• Substituted amide groups are selected from
• R 6 and R 7 are independently selected from hydrogen, loweralkyl, cycloalkyl, loweralkenyl,
• aryl group is substituted with one, two or three substituents independently selected from loweralkyl, alkoxy, thioalkoxy, carboxy, carboalkoxy, cyano, haloalkyl, -N 3 , -NHP 4 wherein P 4 is an N-protecting group, -OP 5 wherein P 5 is an Q-protecting group, nitro, halogen, hydroxy, amino, alkylamino and dialkylamino.
• Functionalized carbonyl groups are selected from
• R 3 is -OH, -OR 4 wherein R 4 is independently as defined above, -NR 6 R 7 wherein R 6 and R 7 are independently as defined above, or -NHR 4 wherein R 4 is independently as defined above.
• Nitrogen containing rings wherein R 1 , R 2 and the adjacent nitrogen atom form a ring are represented by the formula
• R 20 is i) hydrogen, ii) loweralkyl, or iii) loweralkenyl.
• B is i) -(CH 2 ) m -, ii) substituted alkenylene, iii) -QCH 2 - wherein Q is O, S, or
• Ar is a heterocyclic group , aryl or substituted aryl .
• D is group of the formula
• R 30 is hydrogen, loweralkyl, arylalkyl, (substituted aryl) alkyl, or an N-protecting group; and R 5 is independently as defined above.
• the compounds of the invention are cholecystokinin antagonists of the formula:
• R 6 and R 7 are independently selected from hydrogen, loweralkyl, cycloalkyl, loweralkenyl,
• aryl group is substituted with one, two or three substituents independently selected from loweralkyl, alkoxy, thioalkoxy, carboxy, carboalkoxy, cyano, haloalkyl, -N 3 , -NHP 4 wherein P 4 is an N-protecting group, -OP 5 wherein P 5 is an O-protecting group, nitro, halogen, hydroxy, amino, alkylamino and dialkylamino; x) cyclic group wherein R 1 and R 2 taken together with the adjacent nitrogen atom form a heterocyclic group represented by the formula
• R 5 is one, two or three of the substituents independently selected from the group -(C 1 -C 6 loweralkyl), loweralkenyl,
• R 12 is a heterocyclic group; with the proviso that R 1 and R 2 are not both hydrogen;
• R 11 is i) hydrogen, ii) loweralkyl, or iii) loweralkenyl
• R 20 is i) hydrogen, ii) loweralkyl, or iii) loweralkenyl
• R 18 are independently as def ined above , iii ) -QCH 2 - wherein Q is O , S , or
• European Patent Application No. 0230151 published July 29, 1987, discloses the following compounds as CCK antagonists:
• Ar is phenyl or phenyl substituted with one or two substituents independently selected from hydrogen, loweralkyl, alkoxy, hydroxy substituted alkyl, alkoxy substituted alkyl, halogen, amino, hydroxy, nitro, cyano, carboxy, ethoxycarbonyl and trihalomethyl; and R 1 is -(CH 2 ) phenyl wherein a is 1 to 4; and R 2 is loweralkyl, cycloalkyl, -(CH 2 ), aryl wherein b is 0 to 4, -(CH 2 ) b (substituted aryl) wherein b is 0 to 4 and substituted aryl is as defined above, or -(CH 2 ) c (CO)R 3 wherein c is 1 to 4 and R 3 is hydroxy, alkoxy, -O(CH 2 ) c aryl,
• the “dashed” bond in the compound of Formula I indicates that the bond is a single bond or a double bond.
• loweralkyl refers to straight or branched chain alkyl radicals containing from 1 to 6 carbon atoms including but not limited to methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 2 ,2-dimethylbutyl, and the like.
• cycloalkyl refers to an alicyclic ring having 3 to 7 carbon atoms including, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
• loweralkenyl refers to a lower alkyl radical which contains at least one carbon-carbon double bond.
• loweralkynyl refers to a lower alkyl radical which contains at least one carbon-carbon triple bond.
• alkylene group refers to a (CH 2 ) y radical where y is 1 to 5, such as methylene, ethylene, propylene, tetramethylene and the like.
• alkenylene group refers to a C 2 -C 5 chain of carbon atoms which contains at least one carbon-carbon double bond, such as vinylene,- propenylene, butenylene and the like.
• halogen or halo as used herein refers to F, Cl, Br, I.
• alkoxy and thioalkoxy refer to R 9 O- and R 9 S- respectively, wherein R 9 is a loweralkyl group.
• alkoxyalkyl refers to an alkoxy group appended to a loweralkyl radical including, but not limited to, methoxymethyl, ethoxypropyl and the like.
• alkylamino refers to -NHR 13 wherein R 13 is a loweralkyl group.
• dialkylamino refers to -NR 14 R 15 - wherein R 14 and R 15 are independently selected from loweralkyl.
• aminoalkyl refers to an amino group (-NH 2 ) appended to a loweralkyl radical including, but not limited to, aminomethyl, aminoethyl and the like.
• aminoalkenyl refers to an amino group appended to a loweralkenyl radical, with the proviso that the amino group is not bonded directly to the double bond of the alkenyl group. Examples include, but are not limited to, 4-amino-but-2-enyl and the like.
• aminocarbonyl refers to -C(O)NH 2 .
• alkylaminocarbonyl refers to -C(O)NHR 19 wherein R 19 is a loweralkyl group.
• dialkylaminocarbonyl refers to -C(O)NR 19 R 20 wherein R 19 and R 20 are independently selected from loweralkyl.
• alkoxycarbonyl refers to -C(O)R 16 wherein R 16 is an alkoxy group.
• Carboaryloxy refers to -C(O)R 17 wherein R 17 is an aryloxy group.
• haloalkyl refers to a loweralkyl radical substituted by one or more halogens including, but not limited to, chloromethyl, 1,2-dichloroethyl, trifluoromethyl and the like.
• aryl or "aryl group” as used herein refers to phenyl, naphthyl, indanyl, fluorenyl, (1,2,3,4)-tetrahydronaphthyl, indenyl or isoindenyl.
• substituted aryl refers to an aryl group substituted with one, two or three substituents independently selected from the group including but not limited to loweralkyl, alkoxy, halogen, thioalkoxy, carboxy, carboalkoxy, cyano, haloalkyl, -N 3 , -NHP 4 wherein P 4 is an N-protecting group, -OP 5 wherein P 5 is an O-protecting group, nitro, hydroxy, amino, alkylamino and dialkylamino.
• arylalkyl refers to an aryl group appended to a loweralkyl radical including, but not limited to, benzyl and the like.
• (substituted aryl)alkyl refers to a substituted aryl group appended to a loweralkyl radical including, but not limited to, 4-methoxybenzyl and the like.
• heterocyclic refers to any 5-, 6- or 7-membered ring containing from one to three heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur; wherein the 5-membered ring has 0-2 double bonds, 6-membered ring has 0-3 double bonds and the 7-membered ring has 0-3 double bonds; wherein the nitrogen and sulfur heteroatoms can be oxidized; wherein the nitrogen heteroatom can be quaternized; and including any bicyclic or tricyclic group in which the above-mentioned heterocyclic ring is fused to one or two benzene rings or one or two 5-membered or 6-membered heterocyclic rings as defined above.
• heterocycles include, but are not limited to, thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, oxatriazolyl, pyrrolidinyl, pyrrolmyl, imidazolidinyl, imidazolinyl, pyrazolidmyl, triazolyl, tetrahydrofuryl, pyranyl, pyronyl, pyridyl, pyrazinyl, pyridazinyl, piperidyl, piperazinyl, morpholinyl, thiazinyl, oxadiazinyl, azepinyl, thiapinyl, thionaphthyl, benzofuryl, isobenzofuryl, indolyl, oxyindolyl, isoin
• the heterocyclic groups can be unsubstituted or substituted with one, two or three substituents independently selected from hydroxy, oxo, amino, alkylamino, dialkylamino, alkoxy, thioalkoxy, carboxyl, alkoxycarbonyl, halo, haloalkyl, loweralkyl, cyano, aminoalkyl, aminoalkenyl, azide, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, nitro, thiocyanate, alkenyloxy, thioalkenyloxy, aryloxy, thioaryloxy, -OP 1 and -NHP 2 wherein P 1 is an O-protecting group and P 2 is an N-protecting group.
• aryloxy or “thioaryloxy” as used herein refers to R 10 O- or R 10 S-, respectively, wherein R 10 is an aryl or substituted aryl group.
• N-protecting group or “N-protected” as used herein refers to those groups intended to protect the N-terminus of an amino acid or peptide or to protect an amino group against undersirable reactions during synthetic procedures or to prevent the attack of exopeptidases on the compounds or to increase the solubility of the compounds and includes but is not limited to sulfonyl, acyl, acetyl, pivaloyl, t-butyloxycarbonyl (Boc), carbonylbenzyloxy (Cbz), benzoyl or an L- or D-aminoacyl residue, which may itself be N-protected similarly.
• O-protecting group refers to a substituent which protects hydroxyl groups against undesirable reactions during synthetic procedures and includes but is not limited to substituted methyl ethers, for example methoxymethyl, benzylozymethyl, 2-methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, benzyl and triphenylmethyl; tetrahydropyranyl ethers; substituted ethyl ethers, for example, 2,2,2-trichloroethyl and t-butyl; and silyl ethers, for example, trimethylsilyl, t-butyldimethylsilyl and t-butyldiphenylsi lyl .
• Trp refers to tryptophan
• Exemplary compounds of the invention include, but are not limited to:
• N-(2'-Indolylcarbonyl)-R-Tryptophan-di-n-pentylamide N-(3'-Quinolylcarbonyl)-R-Tryptophan-benzylamide, N-(2'-Indolylcarbonyl)-Tryptophan-(1',R-phenylethyl)amide, N-(3'-Quinolylcarbonyl)-R-Tryptophan-di-n-pentylamide, Methyl N-(2'-Indolylcarbonyl)-R-Tryptophyl-S-Phenylglycinate, Ethyl N-(2'-Indolylcarbonyl)-R-Tryptophyl-S- Phenylglycinate,
• Preferred compounds of the invention include N-(2'-Indolylcarbonyl)-R-Tryptophan-di-n-pentylamide, N-(3'-Qumolylcarbonyl)-R-Tryptophan-di-n-pentylamide, N-(3'-Quinolylcarbonyl)-R-(beta-Oxindolyl)Alanine-di-n-pentylamide
• the compounds of the invention may be made as shown in Scheme I. Compounds with DL (R,S), L, or D configuration may be used in the synthetic schemes.
• N-protected derivatives of tryptophan 1 are coupled with primary and secondary amines of the type HNR 1 R 2 (preferably dialkyl, diaryl, or arylalkyl amines or amino acid esters) using bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOPCl) or other standard coupling techniques (i.e., isobutylchloroformate (IBCF), phosphorus pentachloride (PCl 5 ), dicyclohexylcarbodiimide (DCC), or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) with hydroxybenzotriazole (HOBt)).
• BOPCl bis(2-oxo-3-oxazolidinyl)phosphinic chloride
• IBCF isobutylchloroformate
• PCl 5 phosphorus pentachloride
• DCC dicyclohexylcarbodiimi
• Both the salt 3 and the free base 4 are coupled to an appropriate arylcarboxylic acid or heteroarylcarboxylic acid (preferably quinoline-3-carboxylic acid or indole-2-carboxylic acid) using standard techniques to provide product 5 .
• 5 can be obtained from the coupl ing of 3 or 4 with the appropriate acid chloride or activated ester form of the aryl- or heteroarylcarboxylic acids. Further substitution of the nitrogem atom can be achieved via prior alkylation.
• the amine 4 or its hydrochloride 3 is either directly alkylated with R 11 X (where X is chloride, bromide, iodide), an activated form of the alcohol R 11 OH or reductively alkylated with an appropriate aldehyde in the presence of a reducing agent such as sodium cyanoborohydride or sodium borohydride, to provide the same product 6.
• Product 5 can then be coupled in a fashion analogous to 3 and 4 to provide the key compound 5 .
• Compound 5 can be treated directly with aryl- or alkylsulfenyl chlorides (R 10 SCl or R 9 SCl) in a variety of solvents to provide the thioaryl or thioalkyl substituted tryptophans 1 .
• the tricyclic intermediate 17 can be produced from 5 via the action of t-butylhypochlorite and an amine base and the tricyclic 17 reacted with thiols R 10 SH or R 9 SH to provide the substituted analogs 7 .
• the product 5 can also be treated with base (sodium hydride, sodium hydroxide under phase transfer conditions, or lithium hexamethyldisilazide in dimethylformamide (DMF)) followed by an alkylating or acylating agent represented by R 30 X, to provide the derivatized products 8.
• base sodium hydride, sodium hydroxide under phase transfer conditions, or lithium hexamethyldisilazide in dimethylformamide (DMF)
• R 30 X alkylating or acylating agent represented by R 30 X
• the amine hydrochloride 3 or it substituted analog 6 can likewise be coupled with aryl- or heteroarylsulfonylchlorides (ArSO 2 Cl) to provide the products 9.
• aryl- or heteroarylsulfonylchlorides ArSO 2 Cl
• one familiar with the art could use the sulfonic acids and standard coupling methodology to provide 9.
• the amines 3 and 6 may also be coupled in standard fashion to the beta aryl- or beta heteroaryl substituted acrylic acids ( or their corresponding acid chlorides) to yield the unsaturated derivatives 10.
• Compound 11 is obtained through direct oxidation of the parent 5 with hydrochloric acid in dimethylsulfoxide (DMSO). Alternatively, controlled hydrolysis of intermediate 17 yields compound 11.
• Indoline derivatives of the type 12 are obtained by the catalytic hydrogenation of 5 followed by an acylation or an alkylation.
• Compounds of the type 1 are obtained by an alkylation sequence starting from compound 13.
• Compound 14 is alkylated directly with R 11 X utilizing phase transfer conditions (methylene chloride, or other suitable organic solvent, and 10-50% sodium or potassium hydroxide solutions or potassium carbonate) with a tetraalkylammonium salt present, preferably tetrabutylammonium hydrogensulfate (NBu 4 HSO 4 ).
• a tetraalkylammonium salt present, preferably tetrabutylammonium hydrogensulfate (NBu 4 HSO 4 ).
• the product 15 is deprotected with aqueous acid and subsequently the free amine or its salt is protected with CbzCl or di-t-butyldicarbonate (Boc 2 O) to yield the ester 16.
• Ester 16 is saponified in a standard fashion (NaOH) to provide 1 (R 11 not H) for subsequent reaction including conversion to products of types 5, 7 , 8 , 9 and 10.
• R 4 and R 4 are independently selected from i) hydrogen, ii) C 1 -C 6 loweralkyl, iii) cycloalkyl, iv) loweralkenyl, v) -(CH 2 ) m cycloalkyl.
• R 4 and R 4 are independently selected from i) hydrogen, ii) C 1 -C 6 loweralkyl, iii) cycloalkyl, iv) loweralkenyl, v) -(CH 2 ) m cycloalkyl.
• vi) -(CH 2 ) m CN, vii) alkoxyalkyl, viii) adamantyl, ix) -(CH 2 ) m (C O) r NR 6 R 7 wherein
• R 6 and R 7 are independently selected from hydrogen, loweralkyl, cycloalkyl, loweralkenyl,
• aryl group is substituted with one, two or three substituents independently selected from loweralkyl, alkoxy, thioalkoxy, carboxy, carboalkoxy, cyano, haloalkyl, -N 3 , -NHP 4 wherein P 4 is an N-protecting group, -OP 5 wherein P 5 is an 0-protecting group, nitro, trihalomethyl, halogen, hydroxy, amino, alkylamino and dialkylamino; x) cyclic groups wherein R 1 and R 2 taken together with the adjacent nitrogen atom form a heterocyclic group represented by the formula
• R 21 and R 18 are independently selected from the group hydrogen
• R 21 and R 18 are independently as defined above and -OR 4 wherein R 4 is independently as defined above, -NR 6 R 7 wherein R 6 and R 7 are independently as defined above, or -NHR 4 wherein R 4 is independently as defined above, with the proviso that when R 3 is NR 6 R 7 then R 21 and R 18 are not both hydrogen and xiv) -(C(R 21 )(R 18 )) m R 12 wherein R 21 and R 18 are independently as defined above and
• R 12 is a heterocyclic group; with the proviso that R 1 and R 2 are not both hydrogen; R 11 is i) hydrogen, ii) loweralkyl, or iii) loweralkenyl;
• R 20 is i) hydrogen, ii) loweralkyl, or iii) loweralkenyl; the subscripts are independently selected at each occurrence from the values n is 1 to 3; m is 0 to 4; p is 0 to 2; q is 0 or 1; r is 0 to 1; and t is 0 to 1; and P 3 and P 6 are independently selected from hydrogen and an N-protecting group.
• Ar is a heterocyclic group, aryl or substituted aryl wherein substituted aryl is as defined above; m is 0 to 4; and q is 0 or 1.
• Activating groups are those functional groups which activate a carboxylic acid or sulfonic acid group toward coupling with an amine to form an amide or sulfonamide bond.
• Activating groups Z' include, but are not limited to -OH, -SH, alkoxy, thioalkoxy, halogen, formic and acetic acid derived anhydrides, anhydrides derived from alkoxycarbonyl halides such as isobutyloxycarbonylchloride and the like, N-hydroxysuccinimide derived esters, N-hydroxyphthalimide derived esters, N-hydroxybenzotriazole derived esters,
• N-hydroxy-5-norbornene-2,3-dicarboxamide derived esters 4-nitrophenol derived esters, 2,4,5-trichlorophenol derived esters and the like.
• N-t-Butyloxycarbonyl-R-Tryptophan (10 g, 33 mmol) was stirred at 0°C in 160 mL of methylene chloride (CH 2 Cl 2 ) with bis(2-oxo-3-oxazolidnyl )phosphinic chloride (BOPCl, 8.6 g, 34 mmol), 4.5mL (32 mmol) of triethylamine (TEA).
• di-n-pentylamine 18 mL, 89 mmol
• the mixture was stirred overnight and allowed to warm to room temperature.
• An additional equivalent of BOPCl was added after 18 hrs and the reaction stirred an additional day at ambient temperature.
• reaction sequence was performed similarly to that in example 7 utilizing 90 mg of the hydrochloride salt of example 6, indole-2-carboxylic acid (80 mg), EDCI(120 mg), HOBt (55 mg), and TEA (125 ⁇ L ).
• EDCI (1.91 g, 10 mmol) was added to a cooled (4°C) solution containing quinoline-3-carboxylic acid (1.73 g, 10 mmol), tryptophan methyl ester hydrochloride (2.55 g, 10 mmol), and (2.8 mL, 20 mmol) in 50 mL of methylene chloride. After 4 hrs, the solvent was evaporated and the residue dissolved in ethylacetate and extracted three times with 1 M H 3 PO 4 (phosphoric acid), three times with 1 M Na 2 CO 3 (sodium carbonate), three times with brine and then dried over MgSO 4 . The solution was filtered and concentrated.
• EDCI 190 mg, 1.0 mmol was added to a cooled (4°C) solution of N-(3'-Quinolylcarbonyl)-R-Tryptophan (360 mg, 1.0 mmol), 3-methyl-5-phenylpyrazole (200 mg), HOBt (130 mg, 1.0 mmol), and TEA (140 ⁇ L , 1.0 mmol) in CH 2 Cl 2 (20 mL). The reaction was allowed to attain room temperature overnight. The solvents were evaporated and the residue was dissolved in EtOAc and extracted with 1 M H 3 PO 4 (3x), H 2 O (3x) then dried over MgSO 4 , filtered and concentrated in vacuo.
• EDCI (191 mg, 1.0 mmol) was added to a cooled solution (4°C) of Boc-R-Tryptophan (304 mg, 1.0 mmol), S-Phenylglycine me thyl ester (202 mg, 1.0 mmol), HOBt (135 mg, 1.0 mmol) and TEA (279 ⁇ L, 2.0 mmol) in dry CH 2 Cl 2 (10 mL).
• the reaction was allowed to reach ambient temperature overnight.
• the solvents were evaporated in vacuo and the residue was dissolved in EtOAc and extracted successively with 1 M H 3 PO 4 (3x), 1 M Na 2 CO 3 (3x), brine (3x) then dried over MgSO 4 , filtered and the filtrate concentrated in vacuo.
• EDCI 75 mg, 0.39 mmol was added to a cooled (4°C) solution of indole-2-carboxylic acid (63 mg, 0.39 mmol), methyl R-Tryptophyl-S-Phenyglycinate hydrochloride (150 mg, 0.39 mmol), HOBt (53 mg, 0.39 mmol), and TEA (112 ⁇ L , 0.8 mmol) in CH 2 Cl 2 (10 mL). The reaction was allowed to attain ambient temperature overnight. Additional indole-2-carboxylic acid (6 mg), EDCI (8 mg) and TEA (12 ⁇ L ) were added and the reaction was continued 6 hours.
• Boc-R-Tryptophan (1.43 g, 4.7 mmol), ethyl N-benzylglycinate (1.04 g, 5.4 mmol), EDCI (1.05 g, 5.48 mmol), and HOBt (500 mg, 3.7 mmol) were stirred in 10 mL of DMF at 0°C and TEA (700 ⁇ L ) was added. The reaction was allowed to stir overnight and warm to ambient temperature. The reaction mixture was treated in an analogous fashion to that in example 23 and chromatography with EtOAc/hexane as the elutant mixture provided 1.43 g of an oily product after evaporation of the solvents in vacuo.
• EDCI (82 mg, 0.43 mmol) was added to a cooled (4°C) solution of indole-2-carboxylic acid (69 mg, 0.43 mmol) ethyl R-Tryptophan-(N-benzyl )glycinate hydrochloride (104 mg, 0.43 mmol), HOBt (58 mg, 0.43 mmol), and TEA (120 ⁇ L , 0.86 mmol) in CH 2 Cl 2 (10 mL). The reaction was allowed to attain ambient temperature overnight. Additional EDCI (8 mg) and TEA (12 ⁇ L ) were added after 1 day.
• EDCI 104 mg, 0.54 mmol was added to a cooled (4°C) solution of quinoline-3-carboxylic acid (94 mg, 0.54 mmol), ethyl R-Tryptophan-(N-benzyl)glycinate hydrochloride (217 mg, 0.54 mmol), and TEA (151 ⁇ L , 1.08 mmol) in CH 2 Cl 2 (10 mL).
• the reaction was allowed to attain ambient temperature overnight. After 5 hours, the solvent was evaporated and the residue was dissolved in EtOAc and extracted with 1 M H 3 PO 4 (3x), 1 M Na 2 CO 3 (3x), brine (3x) the dried over MgSO 4 , filtered and the filtrate concentrated.
• EDCI 27 mg, 0.14 mmol was added to a cooled (4°C) solution of N-(3'-Qumolylcarbonyl)-R-Tryptophan (50 mg, 0.14 mmol), methyl R-Phenylglycinate hydrochloride (28 mg, 0.14 mmol), HOBt (19 mg, 0.14 mmol), and TEA (39 ⁇ L, 0.28 mmol) in CH 2 Cl 2 (5 mL).
• MS(FAB) m/e 507(m+H) + , 342, 334, 314.
• EDCI 27 mg, 0.14 mmol was added to a cooled (4°C) solution of N-(3'-Quinolylcarbonyl)-R-Tryptophan (50 mg, 0.14 mmol), methyl S-Phenylglycinate hydrochloride (28 mg, 0.14 mmol), HOBt (19 mg, 0.14 mmol), and TEA (39 ⁇ L, 0.28 mmol) in CH 2 Cl 2 (5 mL). The reaction was allowed to attain room temperature overnight. The reaction mixture was not homogeneous and an additional quantity of TEA (4 ⁇ L ) was added.
• Crop 1 12 mg, 0.024 mmol, 17%.
• BOPCl (128 mg, 0.50 mmol) was added to a cooled (4°C) solution of N-(3'-Quinolylcarbonyl)-R-Tryptophan (180 mg, 0.50 mmol), N-methylbenzylamine (130 ⁇ L , 1.0 mmol), and HOBt (68 mg, 0.50 mmol) in CH 2 Cl 2 (10 mL). The reaction was allowed to attain room temperature overnight. An additional quantity of BOPCl (13 mg) was added and the reaction was continued.
• BOPCl 255 mg, 1.0 mmol was added to a cooled solution (4°C) of Boc-R-Tryptophan (304 mg, 1.0 mmol), S- ⁇ -methylbenzylamine (129 ⁇ L , 1.0 mmol), HOBt (135 mg, 1.0 mmol) and TEA (140 ⁇ L , 1.0 mmol) in dry THF (15 mL). After 2 hours, the solvents were evaporated in vacuo and the residue was dissolved in EtOAc and extracted successively with 1 M H 3 PO 4 (3x), 1 M Na 2 CO 3 (3x), brine (3x) then dried over MgSO 4 , filtered and the filtrate concentrated in vacuo.
• BOPCl 255 mg, 1.0 mmol was added to a cooled solution (4°C) of Boc-R-Tryptophan (304 mg, 1.0 mmol), R- ⁇ -methylbenzylamine (129 ⁇ L, 1.0 mmol), HOBt (135 mg, 1.0 mmol) and TEA (140 ⁇ L , 1.0 mmol) in dry THF (15 mL).
• the reaction was allowed to reach ambient temperature overnight.
• the solvents were evaporated in vacuo and the residue was dissolved in EtOAc and extracted successively with 1 M H 3 PO 4 (3x), 1 M Na 2 CO 3 (3x), brine (3x) then dried over MgSO 4 , filtered and the filtrate concentrated in vacuo.
• Boc-R-Tryptophan-(1',R-phenylethyl)amide 200 mg, 0.49 mmol was mixed with HCl-Dioxane (1.2 mL, 4.9 mmol, pre-cooled to 4°C) under an N 2 atmosphere at ambient temperature. After 2 hours, the volatiles were evaporated in vacuo and placed under high vacuum overnight to provide the product.
• BOPCl (152 mg, 0.60 mmol) was added to a cooled (4°C) solution of N-(3'-quinolylcarbonyl)-R-Tryptophan (200 mg, 0.56 mmol), perhydroisoquinoline (192 mg, 1.4 mmol, prepared by catalytic reduction of isoquinoline (cf. Witkop J Am Chem Soc, 70, 2617-19, 1948), TEA (84 ⁇ L, 0.6 mmol) and HOBt (81 mg , 0.60 mmol) in THF (10 mL). The reaction was allowed to attain room temperature overnight. The solvents were evaporated and the residue treated as in example 18.
• BOPCl (152 mg, 0.60 mmol) was added to a cooled (4°C) solution of N-(3'-quinolylcarbonyl)-R-Tryptophan (200 mg, 0.56 mmol), dibenzylamine (268 ⁇ L , 1.4 mmol), TEA (84 ⁇ L , 0.6 mmol) and HOBt (81 mg, 0.60 mmol) in THF (10 mL). The reaction was allowed to attain room temperature overnight. The solvent was evaporated and the residue was treated as in example 18. The product was purified by chromatography on silica eluted with 2:1 to 1:1 hexanes-EtOAc to provide 100 mg of product, 0.186 mmol (33%).
• BOPCl 255 mg, 1.0 mmol was added to a cooled solution (4°C) of Boc-S-Tryptophan (304 mg, 1.0 mmol), 3-aminoquinoline (144 mg, 1.0 mmol), HOBt (13 mg, 0.1 mmol) and TEA (140 ⁇ L , 1.0 mmol) in dry CH 2 Cl 2 (10 mL). The reaction was allowed to reach ambient temperature overnight. The solvents were evaporated in vacuo and the residue was treated as in example 18. The residue was purified by chromatography on silica gel eluted with a 2:1 to 1:1 hexanes-EtOAc gradient. Yield: 195 mg, 0.45 mmol, (45%).
• Boc-S-Tryptophan-N-(3'-quinolyl)amide 164 mg, 0.38 mmol was mixed with HCl-Dioxane (3 mL, 12 mmol, pre-cooled to 4 C) under an N 2 atmosphere at ambient temperature. After 2 hours, the volatiles were evaporated in vacuo and placed under high vacuum overnight to provide the product. MS(CI) m/e 331(m+H) + .
• BOPCl (152 mg, 0.60 mmol) was added to a cooled (4°C) solution of N-(3'-quinolylcarbonyl)-R-Tryptophan (200 mg, 0.56 mmol), 3-aminoquinoline (173 mg, 1.2 mmol, recrystallized from hexanes), TEA (167 ⁇ L , 1.2 mmol) and HOBt (81 mg, 0.60 mmol) in CH-Cl 2 (15 mL). The reaction was allowed to attain room temperature. After 5 hours, the solvents were evaporated and the residue was treated as in example 18. The crude product was crystallized from aqueous ethanol to provide 60 mg, 0.12 mmol (21% yield).
• EDCI 80 mg, 0.42 mmol was added slowly over -3 hours to a cooled (4°C) solution of quinoline-3-carboxylic acid (73 mg, 0.42 mmol), S-(p-hydroxyphenyl)glycine methyl ester hydrochloride (170 mg, 0.42 mmol), HOBt (6 mg, 0.04 mmol), and TEA (117 ⁇ L , 0.84 mmol) in CH 2 Cl 2 (15 mL). After 2 days, an additional 10% equivalent amount of EDCI and TEA were added and the reaction was continued for one day.
• R,S-5-benzyloxytryptophan (2.0 g) was treated with di-t-butyldicarbonate (1.7 g) in a 50% solution of saturated sodium bicarbonate in dioxane at 0°C. The reaction was allowed to warm to ambient temperature and stir overnight. The solvents were evaporated in vacuo and residue partioned between NaOH (1.0 N) and EtOAc. The aqueous portion was then acidified to pH 2.0 using concentrated HCl and the solution extracted with ethylacetate. The EtOAc was dried over MgSO 4 and filtered.
• Example 57 N-(2'-(3'-Methylindenyl)carbonyl)-R-Tryptophan-di-n-pentylamide EDCI (50 mg, 0.26 mmol) was added to a cooled (4°C) solution of 3-methylindene-2-carboxylic acid (45 mg, 0.26 mmol), hydrochloride of example 2 (100 mg, 0.30 mmol), HOBt (7 mg, 0.05 mmol), and TEA (73 ⁇ L, 0.53 mmol) in CH 2 Cl 2 (5 mL). The reaction was allowed to attain ambient temperature overnight. The solvents were evaporated and the residue was treated as in example 18.
• EDCI 57 mg, 0.3 mmol
• 4-hydroxy-3-iodobenzoic acid 79 mg, 0.30 mmol
• hydrochloride of example 2 100 mg, 0.30 mmol
• HOBt 13 mg, 0.1 mmol
• TEA 84 ⁇ L, 0.6 mmol
• CH 2 Cl 2 5 mL
• the reaction was allowed to attain ambient temperature overnight.
• the solvents were evaporated and the residue was treated as in example 18.
• Example 72 The product of example 72 was treated with 1.0 N NaOH in dioxane at ambient temperature. When tlc indicated that the starting material had been consumed, the reaction mixture was concentrated in vacuo and partioned between water and ethylacetate. The aqueous portion was separated and acidified to pH 2.0 and extracted sucessively with EtOAc. The extracts were dried over MgSO 4 and the solution filtered and concentrated. The crude product was treated directly as in example 51 to provide product after chromatography using EtOAc/hexanes as the elutant.
• Example 74 N-(3'-Quinolylcarbonyl)- ⁇ -allyl-Tryptophan-di-n-pentylamide
• example 73 was treated with 4.5 N HCl in dioxane as in example 2 to provide product which was used directly in a coupling reaction analogous to that described in example 21.
• the product was purified by chromatography using EtOAc and hexane.
• N ⁇ -Quinoline-3-(N-hydroxysuccinimide) ester (95 mg, 0.35), and the product of example 76 (0.3 mmol assumed) were dissolved in 10 mL of methylene chloride and treated with TEA (49 ⁇ L , 0.35 mmol). Additional ester (95 mg) and TEA (49 ⁇ L) were added after 1 and again at 2 days. The solvents were evaporated and the residue was extracted as in example 67 and then purified by chromatography eluting with 90:10:0.5 methylene chloride-ethanol-ammonium hydroxide to provide 71 mg, 0.13 mmol (37%) as a yellow glass.
• Di-t-butyldicarbonate (327 mg, 1.5 mmol) was added to 5-hydroxy-R-Tryptophan (250 mg, 1.14 mmol) and TEA (167 ⁇ L, 1.2 mmol) in 10 mL THF and 5 mL of water. After 1 day, the solvent was evaporated and the residue in ethylacetate was extracted with 0.1 M citric acid and water then dried over MgSO 4 and the filtrate concentrated. The product was used directly in the next step.
• N ⁇ -(3'-Quinolylcarbonyl)-R-Tryptophan 360 mg, 1.0 mmol
• 3,5-dimethylpyrazole 96 mg, 1.0 mmol
• HOBt 270 mg, 2.0 mmol
• TEA 140 ⁇ L , 1.0 mmol
• EDCI 20 mg
• the solvents were evaporated and the residue was extracted and purified as in example 67.
• N ⁇ -(3'-Quinolylcarbonyl)-R-Tryptophan 150 mg, 0.49 mmol
• diethanolamine 240 ⁇ L , 2.5 mmol
• BOPCl 127 mg, 0.50 mmol
• the solvents were evaporated and the residue was purified by chromatography on silica gel eluted with 20:1 methylene chloride-ethanol to provide 144 mg, 0.32 mmol (66%).
• R f 0.52 (80:20:1 chloroform-methanol-ammonium hydroxide).
• Boc-S-Tryptophan (1 g, 3.3 mmol), dipentylamine (1.6 mL, 8.2 mmol) and HOBt (446 mg, 3.3 mmol) were dissolved in 25 mL of methylene chloride and treated with BOPCl (841 mg, 3.3 mmol). After 1 day, TEA (460 ⁇ L ) and additional BOPCl (168 mg) were added. After 3 days, the solvents were evaporated and the residue in ethylacetate was extracted with 0.1 M citric acid, 0.1 M NaHCO 3 , and water. After drying over MgSO 4 and concentration of the filtrate, the residue was purified by chromatography on silica gel eluted with 9:1 to 2:1 hexane-ethylacetate step gradient.
• Phenanthrene-3-carboxylic acid 100 mg, 0.45 mmol
• the product of example 2 172 mg, 0.45 mmol
• the crude residue was purified by chromatography on silica gel eluted with a 9:1 to 2:1 hexane-ethylacetate step gradient to yield 92 mg, 0.18 mmol (40%).
• MS(CI) m/e 548(m+H) + , 418, 326.
• 5-Fluoroindole-2-carboxylic acid (269 mg, 1.5 mmol), the product of example 2 (500 mg, 1.31 mmol) were coupled as in example 58 with the following modifications: 10% more EDCI and TEA were added at 6 hours, and 50% more EDCI and TEA were added at 1 day. After 2 days, the reaction mixture was processed as in example 100 to yield 546 mg, 1.08 mmol (82%). MS(CI) m/e 505(m+H) + , 348, 326.
• Example 108 N-(p-Chloropheny1aminothiocarbonyl)-R-Tryptophan-di-n-pentylamide
• the product of example 2 (100 mg, 0.26 mmol) was reacted with 4-chlorophenylisothiocyanate as in example 107 to yield 62 mg, 0.12 mmol (46%).
• mp 138-140°C.
• MS(CI) m/e 513(m+H) + , 356, 344, 326.
• the compounds of Formula I antagonize CCK which makes the compounds useful in the treatment and prevention of disease states wherein CCK or gastrin may be involved, for example, gastrointestinal disorders such as irritable bowel syndrome, ulcers, excess pancreatic or gastric secretion, acute pancreatitis, motility disorders, pain (potentiation of opiate analgesia), central nervous system disorders caused by CCK's interaction with dopamine such as neuroleptic disorders, tardive dyskinesia, Parkinson's disease, psychosis or Gilles de la Tourette Syndrome, disorders of appetite regulatory systems, Zollinger-Ellison syndrome, and central G cell hyperplasia.
• gastrointestinal disorders such as irritable bowel syndrome, ulcers, excess pancreatic or gastric secretion, acute pancreatitis, motility disorders, pain (potentiation of opiate analgesia), central nervous system disorders caused by CCK's interaction with dopamine such as neuroleptic disorders, tardive dyskinesia, Parkinson's disease,
• CCK 8 [Asp-Tyr(SO 3 H)-Met-Gly-Trp-Met-Asp-Phe-NH 2 ] was purchased from Beckman Instruments (Palo Alto, CA) and Peptide International (Louisville, KY). Chymostatin, L-Try-Gly, puromycin, bestatin, EGTA, HEPES and BSA were purchased from Sigma Chemical Co. (St. Louis, MO). [ 125 I]BH-CCK 8 (specific activity, 2200 Ci/mmol) and Aquasol-2 scintillation cocktail were obtained from New England Nuclear (Boston, MA). Male guinea pigs, 250 to 325 g, were obtained from Scientific Small Animal Laboratory and Farm (Arlington Heights, IL). Collagenase, 300 units per mg, was purchased from Worthington (Frehold, N.J.) Protocol For Radioligand Binding Experiments
• Cortical and pancreatic membrances were prepared as described (Lin and Miller; J. Pharmacol. Exp. Ther. 232, 775-780, 1985). In brief, cortex and pancreas were removed and rinsed with ice-cold saline. Visible fat and connective tissues were removed from the pancreas. Tissues were weighed and homogenized separately in approximately 25 mL of ice-cold 50 mM Tris-HCl buffer, pH 7.4 at 4°C, with a Brinkman Polytron for 30 sec, setting 7. The homogenates were centrifuged for 10 min at 1075 x g and pellets were discarded, the supernatants were saved and centrifuged at 38,730 x g for 20 min.
• the resultant pellets were rehomogenized in 25 mL of 50 mM Tris-HCl buffer with a Teflon-glass homogenizer, 5 up and down strokes.
• the homogenates were centrifuged again at 38,730 x g for 20 min.
• Pellets were then resuspended in 20 mM HEPES, containing 1 mM EGTA, 118 mM NaCl, 4.7 mM KCl, 5 mM MgCl 2 , 100 uM bestatin, 3 uM phosphoramidon, pH 7.4 at 22°C, with a Teflon-glass homogenizer, 15 up and down strokes.
• Resuspension volume for the cortex was 15-18 mL per gm of original wet weight and 60 mL per gm for the pancreas. 2. Incubation Conditions
• [ 125 I]Bolton-Hunter CCK 8 and test compounds were diluted with HEPES-EGTA-salt buffer (see above) containing 0.5% bovine serum albumin (BSA).
• BSA bovine serum albumin
• the cortical tissues were incubated at 30°C for 150 min and pancreatic tissues were incubated at 37°C for 30 min. Incubations were terminated by filtration using Skatron Cell
• Guinea pig acini were prepared by the method of Bruzzone et al. (Biochem. J. 226, 621-624, 1985) as follows. Pancreas was dissected out and connective tissues and blood vessels were removed. The pancreas was cut into small pieces (2mm) by a scissor and placed in a 15 mL conical plastic tube containing 2.5 mL of Krebs-Ringer HEPES (KRH) buffer plus 400 units per mL of collagense.
• KRH Krebs-Ringer HEPES
• the composition of the KRH buffer was: HEPES, 12.5 mM: NaCl, 118 mM; KCl, 4.8 mM; CaCl 2 , 1 mM; KH 2 PO 4 , 1.2 mM; MgSO 4 , 1.2 mM; NaHCO 3 , 5 mM; glucose, 10 mM, pH 7.4.
• the buffer was supplemented with 1% MEM vitamins, 1% MEM amino acids and 0.001% aprotinin.
• the tube was shaken by hand until the suspension appeared homogeneous, usually 5 to 6 min. 5 mL of the KRH, without collagenase and with 0.1% BSA, were added and the tube was centrifuged at 50 x g for 35 sec.
• acini were resuspended in 100 volumes of KRH-3SA buffer, containing 3 uM phosohoramidon and 100 M bestatin. While stirring, 400 uL of acini were added to 1.5 mL microcentrifuge tubes containing 50 uL of CCK 8 , buffer, or test compounds. The final assay volume was 500 uL. Tubes were vortexed and placed in a 37°C waterbath, under 100% O 2 , for 30 min. Afterward, tubes were centrifuged at 10,000 g for 1 min.
• Amylase activity in the supernatant and the cell pellet were separately determined after appropriate dilutions in 0.1% Tr iton X-100, 10 mM NaH 2 PO 4 , pH 7.4 by Abbott Amylase A-gent test using the Abbott Bichromatic Analyzer 200.
• mice Three fasted mice are dosed (p.o.) with the test compound.
• CCK 8 80 ug/kg s.c. is administered with
• charcoal meal 0.1 ml of 10% suspension
• the animals are sacrificed within an additional 5 minutes.
• Gastric emptying defined as the presence of charcoal within the intestine beyond the pyloric sphincter, is inhibited by CCK 8 . Gastric emptying observed in more than one mouse indicates antagonism of
• mice Male mice, 20-30 g, are used in all experiments. The animals are fed with laboratory lab chow and water ad libitum. The compound of Formula I (1-100 mg/kg in 0.2 ml of 0.9% saline) was administered i.p. Ten minutes later CCK 8 (0.2 to 200 nmole/kg in 0.2 ml of 0.9% saline) or saline is injected into the tail vein. Two minutes later the animals are sacrificed and blood is collected into 1.5 ml heparinized polypropylene tubes. The tubes are centrifuged at 10,000 x g for 2 minutes. Insulin levels are determined in the supernatant (plasma) by an RIA method using kits from Radioassy Systems Laboratory (Carson, CA.) or Novo Biolabs (MA.).
• mice Male Swiss CD-I mice (Charles River) (22-27 g) were provided with ample food (Purina Lab Chow) and water until the time of their injection with the test compound.
• ICV injections were given by a free-hand method similar to that previously described (Haley and McCormick, Br. J. Pharmacol. Chemother. 12 12-15 (1957)).
• the animals were placed on a slightly elevated metal grid and restrained by the thumb and forefinger at the level of the shoulders, thus immobilizing their heads.
• Injections were made with a 30 gauge needle with a "stop" consisting of a piece of tygon tubing to limit penetration of the needle to about 4.5 mm below the surface of the skin.
• the needle was inserted perpendicular to the skull at a midline point equidistant from thje eye and an equal distance posterior from the level of the eyes such that the injection site and the two eyes form an equilateral triangle.
• the injection volme (5 ul) was expelled smoothly over a period of approximately 1 second.
• mice were placed in their cages and allowed a 15 minute recovery period prior to the beginning of the behavioral observations.
• mice were placed in clear plastic cages. Each cage measured 19 ⁇ 26 ⁇ 15 centimeters and contained a 60-tube polypropylene test tube rack (NALGENE #5970-0020) placed on end in the center of the cage to enhance exploratory activity. Observations were made evcery 30 seconds for a period of 30 minutes. Behavior was compared between drug and CCK 8 treated mice; CCK 8 treated mice; a;nd mice treated with an equal volume of carrier (usually 0.9% saline or 5% dimethylsulfoxide in water). Locomotion as reported here consisted of either floor locomotion or active climbing on the rack. Differences among groups were analyzed by Newman-Kewels analysis and a probability level of p ⁇ 0.05 was accepted as significant.
• carrier usually 0.9% saline or 5% dimethylsulfoxide in water
• MED minimally effective doses
• the compounds of the present invention can be used in the form of salts derived from inorganic or organic acids.
• These salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate.
• nicotinate 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate.
• the basic nitrogen-containing groups can be guaternized with such agents as loweralkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.
• loweralkyl halides such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides
• dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates
• long chain halides
• the pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of Formula I which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.
• acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid.
• Other salts include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.
• the pharmaceutically acceptable salts of the acid of Formula I are also readily prepared by conventional procedures such as treating an acid of Formula I with an appropriate amount of a base, such as an alkali or alkaline earth metal hydroxide e.g. sodium, potassium, lithium, calcium, or magnesium, or an organic base such as an amine, e.g., dibenzylethylenediamine, trimethylamine, piperidine, pyrrolidine, benzylamine nd the like, or a quaternary ammonium hydroxide such as tetramethylammonium hydroxide and the like.
• a base such as an alkali or alkaline earth metal hydroxide e.g. sodium, potassium, lithium, calcium, or magnesium
• an organic base such as an amine, e.g., dibenzylethylenediamine, trimethylamine, piperidine, pyrrolidine, benzylamine nd the like, or a quaternary ammonium hydroxide such as tetramethylammonium hydrox
• the total daily dose administered in single or divided doses may be in amounts, for example, from 0.001 to 1000 mg a day and more usually 1 to 1000 mg.
• Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose.
• the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated, the particular treatment and the particular mode of administration.
• the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy.
• the compounds of the present invention may be administered orally, parenterally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired.
• parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques.
• sterile injectable preparations for example, sterile injectable aqueous or oleagenous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
• the sterile injectable prepartion may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
• acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
• sterile, fixed oils are conventionally employed as a solvent or suspending medium.
• any bland fixed oil may be employed including synthetic mono- or diglycerides.
• fatty acids such as oleic acid find use in the preparation of injectables.
• Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols which are solid at ordinary temperatures but l iquid at the rectal temperature and will therefore melt in the rectum and release the drug.
• Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules.
• the active compound may be admixed with at least one inert diluent such as sucrose lactose or starch.
• Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate.
• the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
• Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsion, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water.
• Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.
• liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used.
• the present compositons in liposome form can contain, in addition to the compounds of the present invention, stabilizers, preservatives, excipients and the like.
• the preferred lipids are the phospholipids and the phophatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art. See, for example, Prescott, ed., Methods in Cell Biology, Vol. XIV, Academic Press, New York, N.Y. pp. 33- (1976).

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Pain & Pain Management (AREA)
• Psychiatry (AREA)
• Crystallography & Structural Chemistry (AREA)
• Toxicology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Indole Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=22649698

Family Applications (2)

Family Applications Before (1)

Country Status (3)

Cited By (1)

Families Citing this family (51)

Citations (6)

Family Cites Families (4)

• 1989
  • 1989-04-04 EP EP19890105864 patent/EP0336356A3/de active Pending
  • 1989-04-04 WO PCT/US1989/001412 patent/WO1989010355A1/en not_active Application Discontinuation
  • 1989-04-04 EP EP19890905266 patent/EP0442878A4/en not_active Withdrawn
  • 1989-04-04 JP JP1505008A patent/JPH03503650A/ja active Pending

Patent Citations (6)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events